You Are Leaving Avistone's Website
You have selected a link that will take you to a site maintained by a third party. Avistone provides this link as a service to website visitors. Avistone is not responsible for the privacy policy of any third party websites. We encourage you to read the privacy policy of every website you visit. Click 'Cancel' to return to Avistone's site or 'Continue' to proceed.
Gliomas Guideline and Expert Consensus
As the first small-molecule targeted drug launched in China for glioma treatment, Vebreltinib has been repeatedly cited and recommended in China's authoritative clinical guideline, which demonstrates the guideline' clear recognition of its therapeutic value.
-
Expert Consensus on Targeted Therapy and Immunotherapy for Glioma (2025)
[Key Recommendation] : (1) Vebreltinib is recommended for adult patients with IDH-mutant WHO grade 4 astrocytoma or glioblastoma with a history of lower-grade glioma who harbor the PTPRZ1-MET fusion gene and have failed previous treatments. (2) The "Penetration Therapy" regimen consisting of Vebreltinib combined with the anti-angiogenic agent bevacizumab and/or the chemotherapeutic agent temozolomide can be adopted for the treatment of recurrent or progressive high-grade glioma.
-
Integrated Diagnosis and Treatment Guidelines for Glioma by the China Anti-Cancer Association (2024 Edition)
[Key Recommendation] : Vebreltinib is recommended for adult patients with IDH mutant astrocytoma (WHO grade 4) with the PTPRZ1-MET fusion who have experienced treatment failure in prior therapies or glioblastoma with LGG history.
